Literature DB >> 9657651

Hyponatremia induced by oxcarbazepine in children.

P Borusiak1, E Korn-Merker, N Holert, H E Boenigk.   

Abstract

We report the case of a 12-year-old girl with severe clinically relevant hyponatremia (118 mmol/l) and hypochloremia (81 mmol/l) during treatment with oxcarbazepine (OCBZ). The adverse effects were rapidly reversible after discontinuation of OCBZ and did not occur when exposed to carbamazepine. We reviewed the charts of 48 patients who received OCBZ as in-patients in our epilepsy centre and found hyponatremia in nine and hypochloremia in four. The mean sodium level of all patients was 139 mmol/l (range 118-150 mmol/l). We did not see any correlation between sodium or chloride levels and dose of OCBZ or blood serum level of the active metabolite 10-OH-carbazepine. We emphasize that children are at risk of developing electrolyte disturbances during treatment with OCBZ and thus the level of at least sodium should be monitored in those patients.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9657651     DOI: 10.1016/s0920-1211(98)00012-6

Source DB:  PubMed          Journal:  Epilepsy Res        ISSN: 0920-1211            Impact factor:   3.045


  4 in total

Review 1.  Oxcarbazepine: an update of its efficacy in the management of epilepsy.

Authors:  K Wellington; K L Goa
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 2.  The safety and tolerability of newer antiepileptic drugs in children and adolescents.

Authors:  Dean P Sarco; Blaise F D Bourgeois
Journal:  CNS Drugs       Date:  2010-05       Impact factor: 5.749

3.  Severe overdosage with the antiepileptic drug oxcarbazepine.

Authors:  J M van Opstal; R Janknegt; J Cilissen; W H V M L'Ortije; J E Nel; F De Heer
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

Review 4.  Oxcarbazepine: a review of its use in children with epilepsy.

Authors:  Lynne Bang; Karen Goa
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.